ABINs inhibit EGF receptor-mediated NF-kappaB activation and growth of EGF receptor-overexpressing tumour cells (Q39962046)

15 September 2017

ABINs inhibit EGF receptor-mediated NF-kappaB activation and growth of EGF receptor-overexpressing tumour cells (English)

1 reference

15 September 2017

1 reference

1 reference

7

1 reference

15 September 2017

L Huang

1

1 reference

15 September 2017

L Verstrepen

2

1 reference

15 September 2017

K Heyninck

3

1 reference

15 September 2017

A Wullaert

4

1 reference

15 September 2017

H Revets

5

1 reference

15 September 2017

P De Baetselier

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

14 July 2008

1 reference

15 September 2017

1 reference

15 September 2017

27

1 reference

15 September 2017

47

1 reference

15 September 2017

6131-6140

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2008.208

15 September 2017

0 references

cites work

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

IkappaB kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IkappaBalpha degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Inhibition of NF-κB Sensitizes A431 Cells to Epidermal Growth Factor-induced Apoptosis, whereas Its Activation by Ectopic Expression of RelA Confers Resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NIK is a component of the EGF/heregulin receptor signaling complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

A20 inhibits NF-kappaB activation independently of binding to 14-3-3 proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Tumour necrosis factor alpha decreases glucose-6-phosphatase gene expression by activation of nuclear factor kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Expression of ErbB2 enhances radiation-induced NF-kappaB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Regulation and function of IKK and IKK-related kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Regulation of ubiquitin-binding proteins by monoubiquitination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Targeting the EGFR pathway for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Deregulated NF-kappaB activity in haematological malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor induces terminal differentiation in human epidermoid carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Cell cycle control as a basis for cancer chemoprevention through dietary agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

New insights into the regulation of TLR signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Beyond IkappaBs: alternative regulation of NF-kappaB activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor receptor (EGFR) signaling in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NF-kappaB in solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Expression of the NF-kappaB inhibitor ABIN-3 in response to TNF and toll-like receptor 4 stimulation is itself regulated by NF-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Ubiquitin: tool and target for intracellular NF-kappaB inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.208

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.208

1 reference

15 September 2017

1 reference